Formycon AG

The Biosimilar Experts

General Information
Company Name
Formycon AG
Founded Year
2012
Location (Offices)
Planegg, Germany +1
Founders / Decision Makers
Number of Employees
189
Industries
Biopharma
Funding Stage
Post Ipo Equity
Social Media

Formycon AG - Company Profile

Formycon AG is a biopharmaceutical company based in Germany and was founded in 1999. The company's mission, coined as The Biosimilar Experts, is to develop high-quality biopharmaceutical medicines, especially biosimilars, with a focus on treatments in ophthalmology, immunology, and other key chronic diseases. Formycon covers the entire value chain from technical development to clinical phase III and the preparation of dossiers for marketing approval. Currently, the company has four biosimilars in development, and it is also working on a COVID-19 drug FYB207. Biosimilars have promising growth prospects, as many biotech drugs are expected to lose their patent protection in the next decade. Analysts estimate that the global sales of biosimilars could exceed $15 billion by 2020 and rise to over $60 billion by 2030. The company's last investment was a €82.84M Post-IPO Equity investment on 29 January 2024, with the investment coming from the Richter Group. Formycon's expertise and dedication to providing affordable medicines to patients indicate potential success in the rapidly growing biosimilars market. With its innovative approach to biopharmaceutical development and a strong investor backing, Formycon AG seems well-positioned to capitalize on the expanding opportunities in the biopharmaceutical industry.

For more information, visit Formycon AG at Fraunhoferstr. 15, 82152 Martinsried/Planegg, Germany. Contact them via phone at +49 (0) 89 - 86 46 67 100 or email at [email protected].

Taxonomy: Biosimilars, Biopharmaceuticals, Ophthalmology, Immunology, Chronic Diseases, Drug Development, Clinical Trials, Regulatory Approval, Biotech Drugs, COVID-19 Drug, GMP Quality Control, Formulation Development, Analytical Services, CMC Regulatory Affairs, Project Management

Funding Rounds & Investors of Formycon AG (2)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity €82.84M 1 Richter Group 29 Jan 2024
Grant €290.00K 1 Bavarian Research Foundation 13 Oct 2020

Latest News of Formycon AG

View All

No recent news or press coverage available for Formycon AG.

Similar Companies to Formycon AG

View All
SK Biopharmaceuticals - Similar company to Formycon AG
SK Biopharmaceuticals SK Biopharmaceuticals is a global pioneer in the development of new drugs
mAbxience - Similar company to Formycon AG
mAbxience From lab to life
Laminar Pharma - Similar company to Formycon AG
Laminar Pharma Biopharmaceutical company performing discovery, rational design and initial clinical development of new MLT-based drugs.
Mabwell - Similar company to Formycon AG
Mabwell Explore Life, Benefit Health
ASPHALION - Similar company to Formycon AG
ASPHALION Scientific and Regulatory Affairs consultancy with offices in Barcelona, Madrid, Pamplona, Munich and London.